The Future of Chimeric Antigen Receptor T Cell Therapy.

Humans Immunotherapy, Adoptive Receptors, Chimeric Antigen / genetics Receptors, Antigen, T-Cell / genetics Neoplasms / therapy Cell- and Tissue-Based Therapy
Adoptive cellular therapy CAR CAR T cell therapy Cellular therapy Chimeric antigen receptor

Journal

Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473

Informations de publication

Date de publication:
12 2023
Historique:
medline: 23 10 2023
pubmed: 14 7 2023
entrez: 13 7 2023
Statut: ppublish

Résumé

Over the last 10 years CAR T cell therapies have been shown to be transformative for B- and plasma-cell malignancies, however the field is only beginning to realize the potential benefit to patients of such therapies. Over the next 10 years it is expected that advances will be made in durable response rates for patients with B/plasma cell malignancies; expansion to T-cell, myeloid, and solid malignancies; and in delivery and manufacturing to transform the field.

Identifiants

DOI: 10.1016/j.hoc.2023.06.005 PMID: 37442674
pubmed: 37442674
pii: S0889-8588(23)00093-X
doi: 10.1016/j.hoc.2023.06.005
pii:
doi:

Substances chimiques

Receptors, Chimeric Antigen 0
Receptors, Antigen, T-Cell 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1215-1219

Subventions

Organisme : NCI NIH HHS
ID : K08 CA241400
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Eric L Smith (EL)

Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: EricL_Smith@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Future of Chimeric Antigen Receptor T Cell Therapy.
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Immunothérapie adoptive › The Future of Chimeric Antigen Receptor T Cell Therapy.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs chimériques pour l'antigène › The Future of Chimeric Antigen Receptor T Cell Therapy.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux antigènes › Récepteurs aux antigènes des cellules T › The Future of Chimeric Antigen Receptor T Cell Therapy.
questionsmedicales.fr › Tumeurs › The Future of Chimeric Antigen Receptor T Cell Therapy.
questionsmedicales.fr › Thérapeutique › Biothérapie › Thérapie cellulaire et tissulaire › The Future of Chimeric Antigen Receptor T Cell Therapy.